From: Intrauterine growth restriction alters kidney metabolism at the end of nephrogenesis
Compound | Identification |
---|---|
P1 | Taurine |
P2 | PE(18:3(6Z,9Z,12Z)/P-18:1(9Z)) |
P3 | N-acetylglutamine |
P4 | (2S)-2-hydroxy-2-(propan-2-yl)butanedioylcarnitine |
P5 | PG(i-12:0/5-iso PGF2VI), PG(5-iso PGF2VI/i-12:0) |
P6 | L-cysteine, D-cysteine |
P7 | PC(15:0/18:2(9Z,12Z)) |
P8 | PS(DiMe(13,5)/MonoMe(13,5)), PS(MonoMe(13,5)/DiMe(13,5)) |
P9 | Cortisol, 18-hydroxycorticosterone, 17a,21-dihydroxy-5b-pregnane-3,11,20-trione |
P10 | PE(22:0/PGJ2), PE(PGJ2/22:0) |
P11 | dADP |
P12 | Inosine |
P13 | Dihydrothymine |
P14 | Galactose 1-phosphate, dolichyl phosphate D-mannose, fructose 1-phosphate, glucose 1-phosphate, D-mannose 1-phosphate, beta-D-fructose 2-phosphate, mannose 6-phosphate, glucose 6-phosphate, beta-D-glucose 6-phosphate, beta-D-fructose 6-phosphate, D-tagatose 6-phosphate, myo-Inositol 1-phosphate, D-myo-inositol 4-phosphate, myo-inositol 6-phosphate, D-myo-inositol 3-phosphate, fructose 6-phosphate, sorbose 1-phosphate |
P15 | L-tryptophan, D-tryptophan, ( ±)-tryptophan |
P16 | PE(16:1(9Z)/18:1(11Z)), PE(16:1(9Z)/18:1(9Z)), PE(18:1(9Z)/16:1(9Z)), PE-NMe2(14:1(9Z)/18:1(9Z)), PE-NMe2(14:1(9Z)/18:1(11Z)), PE-NMe2(18:1(11Z)/14:1(9Z)), PE-NMe2(18:1(9Z)/14:1(9Z)) |
P17 | PI(20:1(11Z)/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), PI(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/20:1(11Z)), PI(22:4(10Z,13Z,16Z,19Z)/18:1(12Z)-2OH(9,10)), PI(18:1(12Z)-2OH(9,10)/22:4(10Z,13Z,16Z,19Z)) |
P18 | Pancrelipase |
P19 | PA(22:4(7Z,10Z,13Z,16Z)/6keto-PGF1alpha), PA(22:4(7Z,10Z,13Z,16Z)/TXB2), PA(6keto-PGF1alpha/22:4(7Z,10Z,13Z,16Z)), PA(TXB2/22:4(7Z,10Z,13Z,16Z)) |
P20 | 7-Hydroxy-3-oxocholanoic acid, 7alpha-hydroxy-3-oxo-5beta-cholan-24-oic acid, 12alpha-hydroxy-3-oxo-5beta-cholan-24-oic acid |
P21 | N-undecanoylglycine |
P22 | Ethyl glucuronide |
P23 | PC(18:1(11Z)/TXB2), PC(TXB2/18:1(11Z)), PC(18:1(9Z)/TXB2), PC(TXB2/18:1(9Z)) |
P24 | CarnocinCP5 |